Recent 8-K filings for LIPO
Highest-materiality recent filing
Lipella Pharmaceuticals files Chapter 11 bankruptcy, plans 363 sale process
- Filed voluntary Chapter 11 petition in Western District of Pennsylvania on March 30, 2026.
- Company intends to pursue a 363 sale process to maximize value for creditors.
-
Lipella Pharmaceuticals files Chapter 11 bankruptcy, plans 363 sale process
Filed voluntary Chapter 11 petition in Western District of Pennsylvania on March 30, 2026.
-
Lipella board member Lori A. Birder resigns effective February 3, 2026
Lori A. Birder resigned from Lipella Pharmaceuticals' Board of Directors, effective immediately on February 3, 2026.
-
Director Naoki Yoshimura to retire from Lipella board effective Dec 31, 2025
Naoki Yoshimura notified Lipella of his intention to retire from the Board of Directors, effective December 31, 2025.
-
Lipella Pharmaceuticals CMO and Board Member Michael Chancellor to retire effective Dec 4, 2025
Dr. Michael Chancellor notified intention to retire as Chief Medical Officer and Board member.
-
All 27 patients completed 4-week treatment; no serious adverse events reported.
-
Lipella Pharmaceuticals Delisted from Nasdaq, Plans to Relist on National Exchange
Delisted from Nasdaq effective June 19, 2025 due to non-compliance with Listing Rules 5100, 5635, and 5640 regarding private placement transactions.
-
Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets
Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.
-
Lipella sets 2025 annual meeting for July 21; record date June 18
2025 annual meeting scheduled for July 21, 2025; record date for voting is June 18, 2025.
-
Lipella receives Nasdaq deficiency notice for preferred stock issuance; faces potential delisting
Nasdaq notified Lipella that its Series C Preferred Stock and Warrant issuances violated Listing Rules 5635(d) and 5640 (shareholder approval and voting rights).
-
Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP
Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).
-
Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement
Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.
-
Lipella increases designated Series C preferred shares from 1,050,000 to 1,260,000
Filed Certificate of Amendment on April 8, 2025, increasing Series C Voting Convertible Preferred Stock designation from 1,050,000 to 1,260,000 shares.
-
Lipella Pharma enters $2.64M ATM equity facility with H.C. Wainwright
ATM agreement for up to $2,641,881 of common stock at market prices.
-
Lipella completes final close of Series B offering ($88.5K) and launches March warrant offering
Final close sold 885 shares of Series B preferred at $100/share for $88,500 gross; net proceeds $73,455.
-
Lipella raises $726k in fourth closing of Series B preferred offering at $2.51 conversion
Gross proceeds of $726,000 from sale of 7,260 Series B shares convertible into 289,241 common shares at $2.51/share.
-
Lipella raises $3.79M in third closing of Series B convertible preferred offering
Sold 37,880 Series B convertible preferred shares at $100 each; gross proceeds $3.788M, net $3.124M after fees.
-
Lipella Pharmaceuticals amends placement agent agreement with Spartan Capital Securities
Second Amendment removes at-the-market facility restrictions and modifies tail provision to require 10% fee on investments from accredited retail investors within one year of termination.
Materiality & sentiment trend
Max materiality 1.00 · Median 0.60 · Most common event other_material